Curcumin Formulations and Trials: What’s New in Neurological Diseases
Abstract
:1. Introduction: The Need to Protect Curcumin in the Body
2. Curcumin and Neurological Disease: Focusing on Mechanism
2.1. Alzheimer’s Disease
2.2. Parkinson’s Disease
2.3. Amyotrophic Lateral Sclerosis
2.4. Multiple Sclerosis
2.5. Spinal Cord Injury
2.6. Stroke
3. Nanoformulated Curcumin: Focusing on Alzheimer’s Disease In Vivo Models
3.1. Diagnostic Tool for Amyloid
3.2. Therapeutic Tool for Alzheimer’s Disease
4. Curcumin: Focusing on Formulations and Cognitive Skills in Human Trials
Study | Year | Target | Treatment | Effect on Cognition | Study Number |
---|---|---|---|---|---|
Baum et al. [124] | 2008 | 34 Alzheimer | Curcumin | No | NCT00164749 |
Ringman et al. [125] | 2012 | 30 mild Alzheimer | Curcumin C3 Complex® | No | NCT00099710 |
Cox et al. [127] | 2015 | 60 healthy adults | Longvida® | Yes | ACTRN12612001027808 |
Rainey-Smith et al. [130] | 2016 | 96 healthy elderly | Biocurcumax® | Limited | ACTRN12611000437965 |
Small et al. [44] | 2018 | 40 healthy adults | Theracurmin® | Yes | NCT01383161 |
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Burapan, S.; Kim, M.; Paisooksantivatana, Y.; Eser, B.E.; Han, J. Thai Curcuma Species: Antioxidant and Bioactive Compounds. Foods 2020, 9, 1219. [Google Scholar] [CrossRef] [PubMed]
- Shishodia, S. Molecular mechanisms of curcumin action: Gene expression. Biofactors 2013, 39, 37–55. [Google Scholar] [CrossRef] [PubMed]
- Veena, V.; Harikrishnan, A.; Khanna, S. Design of new improved curcumin derivatives to multi-targets of cancer and inflammation. Curr. Drug Targets 2020. [Google Scholar] [CrossRef] [PubMed]
- Joe, B.; Vijaykumar, M.; Lokesh, B.R. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit. Rev. Food Sci. Nutr. 2004, 44, 97–111. [Google Scholar] [CrossRef] [PubMed]
- Jaroonwitchawan, T.; Chaicharoenaudomrung, N.; Namkaew, J.; Noisa, P. Curcumin attenuates paraquat-induced cell death in human neuroblastoma cells through modulating oxidative stress and autophagy. Neurosci. Lett. 2017, 636, 40–47. [Google Scholar] [CrossRef] [PubMed]
- Nabavi, S.F.; Sureda, A.; Dehpour, A.R.; Shirooie, S.; Silva, A.S.; Devi, K.P.; Ahmed, T.; Ishaq, N.; Hashim, R.; Sobarzo-Sánchez, E.; et al. Regulation of autophagy by polyphenols: Paving the road for treatment of neurodegeneration. Biotechnol. Adv. 2018, 36, 1768–1778. [Google Scholar] [CrossRef] [PubMed]
- Tsuda, T. Curcumin as a functional food-derived factor: Degradation products, metabolites, bioactivity, and future perspectives. Food Funct. 2018, 9, 705–714. [Google Scholar] [CrossRef]
- Scazzocchio, B.; Minghetti, L.; D’Archivio, M. Interaction between Gut Microbiota and Curcumin: A New Key of Understanding for the Health Effects of Curcumin. Nutrients 2020, 12, 2499. [Google Scholar] [CrossRef]
- Ghosh, S.S.; He, H.; Wang, J.; Korzun, W.; Yannie, P.J.; Ghosh, S. Intestine-specific expression of human chimeric intestinal alkaline phosphatase attenuates Western diet-induced barrier dysfunction and glucose intolerance. Physiol. Rep. 2018, 6, e13790. [Google Scholar] [CrossRef] [Green Version]
- Marczylo, T.H.; Steward, W.P.; Gescher, A.J. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method. J. Agric. Food Chem. 2009, 57, 797–803. [Google Scholar] [CrossRef]
- Hoehle, S.I.; Pfeiffer, E.; Sólyom, A.M.; Metzler, M. Metabolism of curcuminoids in tissue slices and subcellular fractions from rat liver. J. Agric. Food Chem. 2006, 54, 756–764. [Google Scholar] [CrossRef] [PubMed]
- Ravindranath, V.; Chandrasekhara, N. In vitro studies on the intestinal absorption of curcumin in rats. Toxicology 1981, 20, 251–257. [Google Scholar] [CrossRef]
- Bangphumi, K.; Kittiviriyakul, C.; Towiwat, P.; Rojsitthisak, P.; Khemawoot, P. Pharmacokinetics of Curcumin Diethyl Disuccinate, a Prodrug of Curcumin, in Wistar Rats. Eur. J. Drug Metab. Pharmacokinet. 2016, 41, 777–785. [Google Scholar] [CrossRef]
- Al Shoyaib, A.; Archie, S.R.; Karamyan, V.T. Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies? Pharm. Res. 2019, 37, 12. [Google Scholar] [CrossRef]
- Pan, M.H.; Huang, T.M.; Lin, J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos. 1999, 27, 486–494. [Google Scholar] [PubMed]
- Wang, J.; Ghosh, S.S.; Ghosh, S. Curcumin improves intestinal barrier function: Modulation of intracellular signaling, and organization of tight junctions. Am. J. Physiol. Cell Physiol. 2017, 312, C438–C445. [Google Scholar] [CrossRef]
- Holder, G.M.; Plummer, J.L.; Ryan, A.J. The metabolism and excretion of curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) in the rat. Xenobiotica 1978, 8, 761–768. [Google Scholar] [CrossRef] [PubMed]
- Wahlström, B.; Blennow, G. A study on the fate of curcumin in the rat. Acta Pharmacol. Toxicol. (Copenh.) 1978, 43, 86–92. [Google Scholar] [CrossRef] [PubMed]
- Shen, L.; Ji, H.F. The pharmacology of curcumin: Is it the degradation products? Trends Mol. Med. 2012, 18, 138–144. [Google Scholar] [CrossRef]
- Shen, L.; Liu, L.; Ji, H.F. Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications. Food Nutr. Res. 2017, 61, 1361780. [Google Scholar] [CrossRef] [Green Version]
- Di Meo, F.; Margarucci, S.; Galderisi, U.; Crispi, S.; Peluso, G. Curcumin, Gut Microbiota, and Neuroprotection. Nutrients 2019, 11, 2426. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Felice, V.D.; Quigley, E.M.; Sullivan, A.M.; O’Keeffe, G.W.; O’Mahony, S.M. Microbiota-gut-brain signalling in Parkinson’s disease: Implications for non-motor symptoms. Parkinsonism Relat. Disord. 2016, 27, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Zhuang, Z.; Yang, R.; Wang, W.; Qi, L.; Huang, T. Associations between gut microbiota and Alzheimer’s disease, major depressive disorder, and schizophrenia. J. Neuroinflamm. 2020, 17, 288. [Google Scholar] [CrossRef] [PubMed]
- Di Meo, F.; Donato, S.; Di Pardo, A.; Maglione, V.; Filosa, S.; Crispi, S. New Therapeutic Drugs from Bioactive Natural Molecules: The Role of Gut Microbiota Metabolism in Neurodegenerative Diseases. Curr. Drug Metab. 2018, 19, 478–489. [Google Scholar] [CrossRef] [PubMed]
- Jäger, R.; Lowery, R.P.; Calvanese, A.V.; Joy, J.M.; Purpura, M.; Wilson, J.M. Comparative absorption of curcumin formulations. Nutr. J. 2014, 13, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Begum, A.N.; Jones, M.R.; Lim, G.P.; Morihara, T.; Kim, P.; Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang, F.; Hudspeth, B.; et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer’s disease. J. Pharmacol. Exp. Ther. 2008, 326, 196–208. [Google Scholar] [CrossRef] [Green Version]
- Hickey, M.A.; Zhu, C.; Medvedeva, V.; Lerner, R.P.; Patassini, S.; Franich, N.R.; Maiti, P.; Frautschy, S.A.; Zeitlin, S.; Levine, M.S.; et al. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington’s disease. Mol. Neurodegener. 2012, 7, 12. [Google Scholar] [CrossRef] [Green Version]
- Stancioiu, F.; Mihai, D.; Papadakis, G.Z.; Tsatsakis, M.; Spandidos, D.A.; Badiu, C. Treatment for benign thyroid nodules with a combination of natural extracts. Mol. Med. Rep. 2019, 20, 2332–2338. [Google Scholar] [CrossRef]
- Xie, X.; Tao, Q.; Zou, Y.; Zhang, F.; Guo, M.; Wang, Y.; Wang, H.; Zhou, Q.; Yu, S. PLGA nanoparticles improve the oral bioavailability of curcumin in rats: Characterizations and mechanisms. J. Agric. Food Chem. 2011, 59, 9280–9289. [Google Scholar] [CrossRef]
- Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci. 2009, 37, 223–230. [Google Scholar] [CrossRef]
- Tsai, Y.M.; Chien, C.F.; Lin, L.C.; Tsai, T.H. Curcumin and its nano-formulation: The kinetics of tissue distribution and blood-brain barrier penetration. Int. J. Pharm. 2011, 416, 331–338. [Google Scholar] [CrossRef] [PubMed]
- Tiwari, S.K.; Agarwal, S.; Seth, B.; Yadav, A.; Nair, S.; Bhatnagar, P.; Karmakar, M.; Kumari, M.; Chauhan, L.K.; Patel, D.K.; et al. Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway. ACS Nano 2014, 8, 76–103. [Google Scholar] [CrossRef] [PubMed]
- Essa, D.; Kondiah, P.P.D.; Choonara, Y.E.; Pillay, V. The Design of Poly(lactide-co-glycolide) Nanocarriers for Medical Applications. Front. Bioeng. Biotechnol. 2020, 8, 48. [Google Scholar] [CrossRef]
- Khalil, N.M.; do Nascimento, T.C.; Casa, D.M.; Dalmolin, L.F.; de Mattos, A.C.; Hoss, I.; Romano, M.A.; Mainardes, R.M. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloids Surf. B Biointerfaces 2013, 101, 353–360. [Google Scholar] [CrossRef]
- Kim, T.H.; Jiang, H.H.; Youn, Y.S.; Park, C.W.; Tak, K.K.; Lee, S.; Kim, H.; Jon, S.; Chen, X.; Lee, K.C. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int. J. Pharm. 2011, 403, 285–291. [Google Scholar] [CrossRef] [PubMed]
- Vogel, S.M.; Minshall, R.D.; Pilipović, M.; Tiruppathi, C.; Malik, A.B. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am. J. Physiol. Lung Cell Mol. Physiol. 2001, 281, L1512–L1522. [Google Scholar] [CrossRef]
- Liao, S.C.; Hsu, W.H.; Huang, Z.Y.; Chuang, K.L.; Lin, K.T.; Tseng, C.L.; Tsai, T.H.; Dao, A.H.; Su, C.L.; Huang, C.F. Bioactivity Evaluation of a Novel Formulated Curcumin. Nutrients 2019, 11, 2982. [Google Scholar] [CrossRef] [Green Version]
- Sadegh Malvajerd, S.; Azadi, A.; Izadi, Z.; Kurd, M.; Dara, T.; Dibaei, M.; Sharif Zadeh, M.; Akbari Javar, H.; Hamidi, M. Brain Delivery of Curcumin Using Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Preparation, Optimization, and Pharmacokinetic Evaluation. ACS Chem. Neurosci. 2019, 10, 728–739. [Google Scholar] [CrossRef]
- Ray, B.; Bisht, S.; Maitra, A.; Lahiri, D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc™) in the neuronal cell culture and animal model: Implications for Alzheimer’s disease. J. Alzheimers Dis. 2011, 23, 61–77. [Google Scholar] [CrossRef]
- Baj, T.; Seth, R. Role of Curcumin in Regulation of TNF-α Mediated Brain Inflammatory Responses. Recent Pat. Inflamm. Allergy Drug Discov. 2018, 12, 69–77. [Google Scholar] [CrossRef]
- Meng, F.; Asghar, S.; Gao, S.; Su, Z.; Song, J.; Huo, M.; Meng, W.; Ping, Q.; Xiao, Y. A novel LDL-mimic nanocarrier for the targeted delivery of curcumin into the brain to treat Alzheimer’s disease. Colloids Surf. B Biointerfaces 2015, 134, 88–97. [Google Scholar] [CrossRef] [PubMed]
- Maiti, P.; Paladugu, L.; Dunbar, G.L. Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer’s disease. BMC Neurosci. 2018, 19, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kakkar, V.; Kaur, I.P. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem. Toxicol. 2011, 49, 2906–2913. [Google Scholar] [CrossRef] [PubMed]
- Small, G.W.; Siddarth, P.; Li, Z.; Miller, K.J.; Ercoli, L.; Emerson, N.D.; Martinez, J.; Wong, K.P.; Liu, J.; Merrill, D.A.; et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. Am. J. Geriatr. Psychiatry 2018, 26, 266–277. [Google Scholar] [CrossRef] [PubMed]
- Luss, A.N.; Kulikov, P.P.; Romme, S.B.; Andersen, C.L.; Pennisi, C.P.; Docea, A.O.; Kuskov, A.N.; Velonia, K.; Mezhuev, Y.O.; Shtilman, M.I.; et al. Nanosized carriers based on amphiphilic poly-N-vinyl-2-pyrrolidone for intranuclear drug delivery. Nanomedicine 2018, 13, 703–715. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dolati, S.; Marofi, F.; Babaloo, Z.; Aghebati-Maleki, L.; Roshangar, L.; Ahmadi, M.; Rikhtegar, R.; Yousefi, M. Dysregulated Network of miRNAs Involved in the Pathogenesis of Multiple Sclerosis. Biomed. Pharmacother. 2018, 104, 280–290. [Google Scholar] [CrossRef] [PubMed]
- Bianconi, V.; Sahebkar, A.; Atkin, S.L.; Pirro, M. The regulation and importance of monocyte chemoattractant protein-1. Curr. Opin. Hematol. 2018, 25, 44–51. [Google Scholar] [CrossRef]
- Balasubramanian, S.; Eckert, R.L. Keratinocyte proliferation, differentiation, and apoptosis--differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol. Appl. Pharmacol. 2007, 224, 214–219. [Google Scholar] [CrossRef] [Green Version]
- Park, S.Y.; Kim, D.S. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: A drug discovery effort against Alzheimer’s disease. J. Nat. Prod. 2002, 65, 1227–1231. [Google Scholar] [CrossRef]
- Reddy, P.H.; Manczak, M.; Yin, X.; Grady, M.C.; Mitchell, A.; Kandimalla, R.; Kuruva, C.S. Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J. Investig. Med. 2016, 64, 1220–1234. [Google Scholar] [CrossRef] [Green Version]
- Gagliardi, S.; Franco, V.; Sorrentino, S.; Zucca, S.; Pandini, C.; Rota, P.; Bernuzzi, S.; Costa, A.; Sinforiani, E.; Pansarasa, O.; et al. Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer’s Disease. Front. Pharmacol. 2018, 9, 1404. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.J.; Li, Z.H.; Liu, L.; Tang, W.X.; Wang, Y.; Dong, M.R.; Xiao, C. Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer’s Disease. Front. Pharmacol. 2016, 7, 261. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bassani, T.B.; Turnes, J.M.; Moura, E.L.R.; Bonato, J.M.; Cóppola-Segovia, V.; Zanata, S.M.; Oliveira, R.M.M.W.; Vital, M.A.B.F. Effects of curcumin on short-term spatial and recognition memory, adult neurogenesis and neuroinflammation in a streptozotocin-induced rat model of dementia of Alzheimer’s type. Behav. Brain Res. 2017, 335, 41–54. [Google Scholar] [CrossRef]
- Di Martino, R.M.; De Simone, A.; Andrisano, V.; Bisignano, P.; Bisi, A.; Gobbi, S.; Rampa, A.; Fato, R.; Bergamini, C.; Perez, D.I.; et al. Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors. J. Med. Chem. 2016, 59, 531–544. [Google Scholar] [CrossRef] [PubMed]
- Ramkumar, M.; Rajasankar, S.; Gobi, V.V.; Dhanalakshmi, C.; Manivasagam, T.; Justin Thenmozhi, A.; Essa, M.M.; Kalandar, A.; Chidambaram, R. Neuroprotective effect of Demethoxycurcumin, a natural derivative of Curcumin on rotenone induced neurotoxicity in SH-SY 5Y Neuroblastoma cells. BMC Complement. Altern Med. 2017, 17, 217. [Google Scholar] [CrossRef] [Green Version]
- Uryu, K.; Richter-Landsberg, C.; Welch, W.; Sun, E.; Goldbaum, O.; Norris, E.H.; Pham, C.T.; Yazawa, I.; Hilburger, K.; Micsenyi, M.; et al. Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. Am. J. Pathol. 2006, 168, 947–961. [Google Scholar] [CrossRef] [Green Version]
- Sang, Q.; Liu, X.; Wang, L.; Qi, L.; Sun, W.; Wang, W.; Sun, Y.; Zhang, H. Curcumin Protects an SH-SY5Y Cell Model of Parkinson’s Disease against Toxic Injury by Regulating HSP90. Cell Physiol. Biochem. 2018, 51, 681–691. [Google Scholar] [CrossRef]
- Hovanes, K.; Li, T.W.; Munguia, J.E.; Truong, T.; Milovanovic, T.; Lawrence Marsh, J.; Holcombe, R.F.; Waterman, M.L. Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat. Genet. 2001, 28, 53–57. [Google Scholar] [CrossRef]
- Marchetti, B.; Tirolo, C.; L’Episcopo, F.; Caniglia, S.; Testa, N.; Smith, J.A.; Pluchino, S.; Serapide, M.F. Parkinson’s disease, aging and adult neurogenesis: Wnt/β-catenin signalling as the key to unlock the mystery of endogenous brain repair. Aging Cell 2020, 19, e13101. [Google Scholar] [CrossRef]
- Wang, Y.L.; Ju, B.; Zhang, Y.Z.; Yin, H.L.; Liu, Y.J.; Wang, S.S.; Zeng, Z.L.; Yang, X.P.; Wang, H.T.; Li, J.F. Protective Effect of Curcumin Against Oxidative Stress-Induced Injury in Rats with Parkinson’s Disease through the Wnt/β-Catenin Signaling Pathway. Cell Physiol. Biochem. 2017, 43, 2226–2241. [Google Scholar] [CrossRef]
- Martinez-Horta, S.; Horta-Barba, A.; Kulisevsky, J. Cognitive and behavioral assessment in Parkinson’s disease. Expert Rev. Neurother. 2019, 19, 613–622. [Google Scholar] [CrossRef] [PubMed]
- Khatri, D.K.; Juvekar, A.R. Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in mouse model of Parkinson’s disease. Pharmacol. Biochem. Behav. 2016, 150–151, 39–47. [Google Scholar] [CrossRef]
- Darbinyan, L.V.; Hambardzumyan, L.E.; Simonyan, K.V.; Chavushyan, V.A.; Manukyan, L.P.; Badalyan, S.A.; Khalaji, N.; Sarkisian, V.H. Protective effects of curcumin against rotenone-induced rat model of Parkinson’s disease: In vivo electrophysiological and behavioral study. Metab. Brain Dis. 2017, 32, 1791–1803. [Google Scholar] [CrossRef] [PubMed]
- Ahmad, B.; Lapidus, L.J. Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate. J. Biol. Chem. 2012, 287, 9193–9199. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dehghani, Z.; Meratan, A.A.; Saboury, A.A.; Nemat-Gorgani, M. α-Synuclein fibrillation products trigger the release of hexokinase I from mitochondria: Protection by curcumin, and possible role in pathogenesis of Parkinson’s disease. Biochim. Biophys. Acta Biomembr. 2020, 1862, 183251. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Liu, C.; Zhang, J.; Zhang, Y.; Liu, K.; Song, J.X.; Sreenivasmurthy, S.G.; Wang, Z.; Shi, Y.; Chu, C.; et al. A Self-Assembled α-Synuclein Nanoscavenger for Parkinson’s Disease. ACS Nano 2020, 14, 1533–1549. [Google Scholar] [CrossRef]
- Spinelli, K.J.; Osterberg, V.R.; Meshul, C.K.; Soumyanath, A.; Unni, V.K. Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic Mice. PLoS ONE 2015, 10, e0128510. [Google Scholar] [CrossRef]
- Bhatia, N.K.; Srivastava, A.; Katyal, N.; Jain, N.; Khan, M.A.; Kundu, B.; Deep, S. Curcumin binds to the pre-fibrillar aggregates of Cu/Zn superoxide dismutase (SOD1) and alters its amyloidogenic pathway resulting in reduced cytotoxicity. Biochim. Biophys. Acta 2015, 1854, 426–436. [Google Scholar] [CrossRef]
- Kim, G.; Gautier, O.; Tassoni-Tsuchida, E.; Ma, X.R.; Gitler, A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron 2020. [Google Scholar] [CrossRef]
- Lu, J.; Duan, W.; Guo, Y.; Jiang, H.; Li, Z.; Huang, J.; Hong, K.; Li, C. Mitochondrial dysfunction in human TDP-43 transfected NSC34 cell lines and the protective effect of dimethoxy curcumin. Brain Res. Bull. 2012, 89, 185–190. [Google Scholar] [CrossRef]
- Conti, B.; Sugama, S.; Lucero, J.; Winsky-Sommerer, R.; Wirz, S.A.; Maher, P.; Andrews, Z.; Barr, A.M.; Morale, M.C.; Paneda, C.; et al. Uncoupling protein 2 protects dopaminergic neurons from acute 1,2,3,6-methyl-phenyl-tetrahydropyridine toxicity. J. Neurochem. 2005, 93, 493–501. [Google Scholar] [CrossRef] [PubMed]
- Dong, H.; Xu, L.; Wu, L.; Wang, X.; Duan, W.; Li, H.; Li, C. Curcumin abolishes mutant TDP-43 induced excitability in a motoneuron-like cellular model of ALS. Neuroscience 2014, 272, 141–153. [Google Scholar] [CrossRef] [PubMed]
- Ahmadi, M.; Agah, E.; Nafissi, S.; Jaafari, M.R.; Harirchian, M.H.; Sarraf, P.; Faghihi-Kashani, S.; Hosseini, S.J.; Ghoreishi, A.; Aghamollaii, V.; et al. Safety and Efficacy of Nanocurcumin as Add-on Therapy to Riluzole in Patients with Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. Neurotherapeutics 2018, 15, 430–438. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seyedzadeh, M.H.; Safari, Z.; Zare, A.; Gholizadeh Navashenaq, J.; Razavi, S.A.; Kardar, G.A.; Khorramizadeh, M.R. Study of curcumin immunomodulatory effects on reactive astrocyte cell function. Int. Immunopharmacol. 2014, 22, 230–235. [Google Scholar] [CrossRef]
- Kanakasabai, S.; Casalini, E.; Walline, C.C.; Mo, C.; Chearwae, W.; Bright, J.J. Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J. Nutr. Biochem. 2012, 23, 1498–1507. [Google Scholar] [CrossRef]
- Mohajeri, M.; Sadeghizadeh, M.; Najafi, F.; Javan, M. Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacology 2015, 99, 156–167. [Google Scholar] [CrossRef]
- Motavaf, M.; Sadeghizadeh, M.; Babashah, S.; Zare, L.; Javan, M. Dendrosomal nanocurcumin promotes remyelination through induction of oligodendrogenesis in experimental demyelination animal model. J. Tissue Eng. Regen Med. 2020, 14, 1449–1464. [Google Scholar] [CrossRef]
- Machova Urdzikova, L.; Karova, K.; Ruzicka, J.; Kloudova, A.; Shannon, C.; Dubisova, J.; Murali, R.; Kubinova, S.; Sykova, E.; Jhanwar-Uniyal, M.; et al. The Anti-Inflammatory Compound Curcumin Enhances Locomotor and Sensory Recovery after Spinal Cord Injury in Rats by Immunomodulation. Int. J. Mol. Sci. 2016, 17, 49. [Google Scholar] [CrossRef] [Green Version]
- Lin, M.S.; Lee, Y.H.; Chiu, W.T.; Hung, K.S. Curcumin provides neuroprotection after spinal cord injury. J. Surg. Res. 2011, 166, 280–289. [Google Scholar] [CrossRef]
- Gokce, E.C.; Kahveci, R.; Gokce, A.; Sargon, M.F.; Kisa, U.; Aksoy, N.; Cemil, B.; Erdogan, B. Curcumin Attenuates Inflammation, Oxidative Stress, and Ultrastructural Damage Induced by Spinal Cord Ischemia-Reperfusion Injury in Rats. J. Stroke Cerebrovasc. Dis. 2016, 25, 1196–1207. [Google Scholar] [CrossRef]
- Yu, D.S.; Cao, Y.; Mei, X.F.; Wang, Y.F.; Fan, Z.K.; Wang, Y.S.; Lv, G. Curcumin improves the integrity of blood-spinal cord barrier after compressive spinal cord injury in rats. J. Neurol. Sci. 2014, 346, 51–59. [Google Scholar] [CrossRef] [PubMed]
- Yuan, J.; Liu, W.; Zhu, H.; Chen, Y.; Zhang, X.; Li, L.; Chu, W.; Wen, Z.; Feng, H.; Lin, J. Curcumin inhibits glial scar formation by suppressing astrocyte-induced inflammation and fibrosis in vitro and in vivo. Brain Res. 2017, 1655, 90–103. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.; Cao, G.; Yang, G.; Zhang, Y.; Wang, Y.; Song, W.; Xu, Y.; Ma, T.; Liu, R.; Zhang, Q.; et al. Transplantation of activated olfactory ensheathing cells by curcumin strengthens regeneration and recovery of function after spinal cord injury in rats. Cytotherapy 2020, 22, 301–312. [Google Scholar] [CrossRef]
- Daverey, A.; Agrawal, S.K. Neuroprotective effects of Riluzole and Curcumin in human astrocytes and spinal cord white matter hypoxia. Neurosci. Lett. 2020, 738, 135351. [Google Scholar] [CrossRef] [PubMed]
- Lan, C.; Chen, X.; Zhang, Y.; Wang, W.; Wang, W.E.; Liu, Y.; Cai, Y.; Ren, H.; Zheng, S.; Zhou, L.; et al. Curcumin prevents strokes in stroke-prone spontaneously hypertensive rats by improving vascular endothelial function. BMC Cardiovasc. Disord. 2018, 18, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xie, C.J.; Gu, A.P.; Cai, J.; Wu, Y.; Chen, R.C. Curcumin protects neural cells against ischemic injury in N2a cells and mouse brain with ischemic stroke. Brain Behav. 2018, 8, e00921. [Google Scholar] [CrossRef] [Green Version]
- Zhao, J.; Yu, S.; Zheng, W.; Feng, G.; Luo, G.; Wang, L.; Zhao, Y. Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Neurochem. Res. 2010, 35, 374–379. [Google Scholar] [CrossRef]
- Funk, J.L.; Frye, J.B.; Davis-Gorman, G.; Spera, A.L.; Bernas, M.J.; Witte, M.H.; Weinand, M.E.; Timmermann, B.N.; McDonagh, P.F.; Ritter, L. Curcuminoids limit neutrophil-mediated reperfusion injury in experimental stroke by targeting the endothelium. Microcirculation 2013, 20, 544–554. [Google Scholar] [CrossRef]
- Pluta, R.; Bogucka-Kocka, A.; Ułamek-Kozioł, M.; Furmaga-Jabłońska, W.; Januszewski, S.; Brzozowska, J.; Jabłoński, M.; Kocki, J. Neurogenesis and neuroprotection in postischemic brain neurodegeneration with Alzheimer phenotype: Is there a role for curcumin? Folia Neuropathol. 2015, 53, 89–99. [Google Scholar] [CrossRef] [Green Version]
- Shah, F.A.; Gim, S.A.; Sung, J.H.; Jeon, S.J.; Kim, M.O.; Koh, P.O. Identification of proteins regulated by curcumin in cerebral ischemia. J. Surg. Res. 2016, 201, 141–148. [Google Scholar] [CrossRef]
- Huang, L.; Chen, C.; Zhang, X.; Li, X.; Chen, Z.; Yang, C.; Liang, X.; Zhu, G.; Xu, Z. Neuroprotective Effect of Curcumin against Cerebral Ischemia-Reperfusion via Mediating Autophagy and Inflammation. J. Mol. Neurosci. 2018, 64, 129–139. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Yan, Y.; Cao, Y.; Yang, Y.; Zhao, Q.; Jing, R.; Hu, J.; Bao, J. Potential therapeutic and protective effect of curcumin against stroke in the male albino stroke-induced model rats. Life Sci. 2017, 183, 45–49. [Google Scholar] [CrossRef] [PubMed]
- Marques, M.S.; Cordeiro, M.F.; Marinho, M.A.G.; Vian, C.O.; Vaz, G.R.; Alves, B.S.; Jardim, R.D.; Hort, M.A.; Dora, C.L.; Horn, A.P. Curcumin-loaded nanoemulsion improves haemorrhagic stroke recovery in wistar rats. Brain Res. 2020, 1746, 147007. [Google Scholar] [CrossRef] [PubMed]
- Oakley, H.; Cole, S.L.; Logan, S.; Maus, E.; Shao, P.; Craft, J.; Guillozet-Bongaarts, A.; Ohno, M.; Disterhoft, J.; Van Eldik, L.; et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. J. Neurosci. 2006, 26, 10129–10140. [Google Scholar] [CrossRef]
- Lazar, A.N.; Mourtas, S.; Youssef, I.; Parizot, C.; Dauphin, A.; Delatour, B.; Antimisiaris, S.G.; Duyckaerts, C. Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: Possible applications to Alzheimer disease. Nanomedicine 2013, 9, 712–721. [Google Scholar] [CrossRef]
- Hsiao, K.; Chapman, P.; Nilsen, S.; Eckman, C.; Harigaya, Y.; Younkin, S.; Yang, F.; Cole, G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274, 99–102. [Google Scholar] [CrossRef]
- Cheng, K.K.; Chan, P.S.; Fan, S.; Kwan, S.M.; Yeung, K.L.; Wáng, Y.X.; Chow, A.H.; Wu, E.X.; Baum, L. Curcumin-conjugated magnetic nanoparticles for detecting amyloid plaques in Alzheimer’s disease mice using magnetic resonance imaging (MRI). Biomaterials 2015, 44, 155–172. [Google Scholar] [CrossRef]
- Ran, C.; Zhao, W.; Moir, R.D.; Moore, A. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. PLoS ONE 2011, 6, e19362. [Google Scholar] [CrossRef] [Green Version]
- Ran, C.; Xu, X.; Raymond, S.B.; Ferrara, B.J.; Neal, K.; Bacskai, B.J.; Medarova, Z.; Moore, A. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J. Am. Chem. Soc. 2009, 131, 15257–15261. [Google Scholar] [CrossRef] [Green Version]
- Lee, M.-C.; Yu, W.-C.; Shih, Y.-H.; Chen, C.-H.; Guo, Z.-H.; Huang, S.-J.; Chan, J.C.C.; Chen, Y.-R. Zinc ion rapidly induces toxic, off-pathway amyloid-β oligomers distinct from amyloid-β derived diffusible ligands in Alzheimer’s disease. Sci. Rep. 2018, 8, 4772. [Google Scholar] [CrossRef]
- Ahmed, A.; Ghallab, E.H.; Shehata, M.; Zekri, A.N.; Ahmed, O.S. Impact of nano-conjugate on Drosophila for early diagnosis of Alzheimer’s disease. Nanotechnology 2020, 31, 365102. [Google Scholar] [CrossRef] [PubMed]
- Conti, E.; Gregori, M.; Radice, I.; Da Re, F.; Grana, D.; Re, F.; Salvati, E.; Masserini, M.; Ferrarese, C.; Zoia, C.P.; et al. Multifunctional liposomes interact with Abeta in human biological fluids: Therapeutic implications for Alzheimer’s disease. Neurochem. Int. 2017, 108, 60–65. [Google Scholar] [CrossRef] [PubMed]
- Papadia, K.; Giannou, A.D.; Markoutsa, E.; Bigot, C.; Vanhoute, G.; Mourtas, S.; Van der Linded, A.; Stathopoulos, G.T.; Antimisiaris, S.G. Multifunctional LUV liposomes decorated for BBB and amyloid targeting—B. In vivo brain targeting potential in wild-type and APP/PS1 mice. Eur. J. Pharm. Sci. 2017, 102, 180–187. [Google Scholar] [CrossRef] [PubMed]
- Huo, X.; Zhang, Y.; Jin, X.; Li, Y.; Zhang, L. A novel synthesis of selenium nanoparticles encapsulated PLGA nanospheres with curcumin molecules for the inhibition of amyloid β aggregation in Alzheimer’s disease. J. Photochem. Photobiol. B 2019, 190, 98–102. [Google Scholar] [CrossRef] [PubMed]
- Jaruszewski, K.M.; Curran, G.L.; Swaminathan, S.K.; Rosenberg, J.T.; Grant, S.C.; Ramakrishnan, S.; Lowe, V.J.; Poduslo, J.F.; Kandimalla, K.K. Multimodal nanoprobes to target cerebrovascular amyloid in Alzheimer’s disease brain. Biomaterials 2014, 35, 1967–1976. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Egan, K.J.; Vesterinen, H.M.; Beglopoulos, V.; Sena, E.S.; Macleod, M.R. From a mouse: Systematic analysis reveals limitations of experiments testing interventions in Alzheimer’s disease mouse models. Evid. Based Preclin. Med. 2016, 3, e00015. [Google Scholar] [CrossRef] [PubMed]
- Egan, K.J.; Vesterinen, H.M.; McCann, S.K.; Sena, E.S.; MacLeod, M.R. The development of an online database for interventions tested in transgenic mouse models of Alzheimer’s disease. Evid. Based Preclin. Med. 2015, 2, e00010. [Google Scholar] [CrossRef]
- Chen, J.Y.; Zhu, Q.; Zhang, S.; OuYang, D.; Lu, J.H. Resveratrol in experimental Alzheimer’s disease models: A systematic review of preclinical studies. Pharmacol. Res. 2019, 150, 104476. [Google Scholar] [CrossRef]
- Rahman, S.O.; Hussain, S.; Alzahrani, A.; Akhtar, M.; Najmi, A.K. Effect of statins on amyloidosis in the rodent models of Alzheimer’s disease: Evidence from the preclinical meta-analysis. Brain Res. 2020, 1749, 147115. [Google Scholar] [CrossRef]
- Zhang, X.W.; Chen, J.Y.; Ouyang, D.; Lu, J.H. Quercetin in Animal Models of Alzheimer’s Disease: A Systematic Review of Preclinical Studies. Int. J. Mol. Sci. 2020, 21, 493. [Google Scholar] [CrossRef] [Green Version]
- Landis, S.C.; Amara, S.G.; Asadullah, K.; Austin, C.P.; Blumenstein, R.; Bradley, E.W.; Crystal, R.G.; Darnell, R.B.; Ferrante, R.J.; Fillit, H.; et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490, 187–191. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jellinger, K.A. The neuropathological diagnosis of Alzheimer disease. J. Neural Trans. Suppl. 1998, 53, 97–118. [Google Scholar] [CrossRef]
- Gao, C.; Wang, Y.; Sun, J.; Han, Y.; Gong, W.; Li, Y.; Feng, Y.; Wang, H.; Yang, M.; Li, Z.; et al. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer’s disease mice. Acta Biomater. 2020, 108, 285–299. [Google Scholar] [CrossRef] [PubMed]
- Gao, C.; Chu, X.; Gong, W.; Zheng, J.; Xie, X.; Wang, Y.; Yang, M.; Li, Z.; Yang, Y. Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease. J. Nanobiotechnol. 2020, 18, 71. [Google Scholar] [CrossRef]
- Fidelis, E.M.; Savall, A.S.P.; da Luz Abreu, E.; Carvalho, F.; Teixeira, F.E.G.; Haas, S.E.; Bazanella Sampaio, T.; Pinton, S. Curcumin-Loaded Nanocapsules Reverses the Depressant-Like Behavior and Oxidative Stress Induced by β-Amyloid in Mice. Neuroscience 2019, 423, 122–130. [Google Scholar] [CrossRef]
- Giacomeli, R.; Izoton, J.C.; Dos Santos, R.B.; Boeira, S.P.; Jesse, C.R.; Haas, S.E. Neuroprotective effects of curcumin lipid-core nanocapsules in a model Alzheimer’s disease induced by β-amyloid 1-42 peptide in aged female mice. Brain Res. 2019, 1721, 146325. [Google Scholar] [CrossRef]
- Cheng, K.K.; Yeung, C.F.; Ho, S.W.; Chow, S.F.; Chow, A.H.; Baum, L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer’s disease Tg2576 mice. AAPS J. 2013, 15, 324–336. [Google Scholar] [CrossRef] [Green Version]
- Huang, N.; Lu, S.; Liu, X.G.; Zhu, J.; Wang, Y.J.; Liu, R.T. PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer’s disease mice. Oncotarget 2017, 8, 81001–81013. [Google Scholar] [CrossRef] [Green Version]
- Fan, S.; Zheng, Y.; Liu, X.; Fang, W.; Chen, X.; Liao, W.; Jing, X.; Lei, M.; Tao, E.; Ma, Q.; et al. Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease. Drug Deliv. 2018, 25, 1091–1102. [Google Scholar] [CrossRef] [Green Version]
- Chandra, V.; Pandav, R.; Dodge, H.H.; Johnston, J.M.; Belle, S.H.; DeKosky, S.T.; Ganguli, M. Incidence of Alzheimer’s disease in a rural community in India: The Indo-US study. Neurology 2001, 57, 985–989. [Google Scholar] [CrossRef] [Green Version]
- Shaji, S.; Bose, S.; Verghese, A. Prevalence of dementia in an urban population in Kerala, India. Br. J. Psychiatry 2005, 186, 136–140. [Google Scholar] [CrossRef] [PubMed]
- Lafortune, L.; Martin, S.; Kelly, S.; Kuhn, I.; Remes, O.; Cowan, A.; Brayne, C. Behavioural Risk Factors in Mid-Life Associated with Successful Ageing, Disability, Dementia and Frailty in Later Life: A Rapid Systematic Review. PLoS ONE 2015, 11, e0144405. [Google Scholar] [CrossRef] [PubMed]
- Ng, T.P.; Chiam, P.C.; Lee, T.; Chua, H.C.; Lim, L.; Kua, E.H. Curry consumption and cognitive function in the elderly. Am. J. Epidemiol. 2006, 164, 898–906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baum, L.; Lam, C.W.; Cheung, S.K.; Kwok, T.; Lui, V.; Tsoh, J.; Lam, L.; Leung, V.; Hui, E.; Ng, C.; et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J. Clin. Psychopharmacol. 2008, 28, 110–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ringman, J.M.; Frautschy, S.A.; Teng, E.; Begum, A.N.; Bardens, J.; Beigi, M.; Gylys, K.H.; Badmaev, V.; Heath, D.D.; Apostolova, L.G.; et al. Oral curcumin for Alzheimer’s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res. Ther. 2012, 4, 43. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stohs, S.J.; Chen, O.; Ray, S.D.; Ji, J.; Bucci, L.R.; Preuss, H.G. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review. Molecules 2020, 25, 1397. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cox, K.H.; Pipingas, A.; Scholey, A.B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J. Psychopharmacol. 2015, 29, 642–651. [Google Scholar] [CrossRef]
- Gota, V.S.; Maru, G.B.; Soni, T.G.; Gandhi, T.R.; Kochar, N.; Agarwal, M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010, 58, 2095–2099. [Google Scholar] [CrossRef]
- Cox, K.H.M.; White, D.J.; Pipingas, A.; Poorun, K.; Scholey, A. Further Evidence of Benefits to Mood and Working Memory from Lipidated Curcumin in Healthy Older People: A 12-Week, Double-Blind, Placebo-Controlled, Partial Replication Study. Nutrients 2020, 12, 1678. [Google Scholar] [CrossRef]
- Rainey-Smith, S.R.; Brown, B.M.; Sohrabi, H.R.; Shah, T.; Goozee, K.G.; Gupta, V.B.; Martins, R.N. Curcumin and cognition: A randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br. J. Nutr. 2016, 115, 2106–2113. [Google Scholar] [CrossRef]
- Antony, B.; Merina, B.; Iyer, V.S.; Judy, N.; Lennertz, K.; Joyal, S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), a Novel Bioenhanced Preparation of Curcumin. Indian J. Pharm. Sci. 2008, 70, 445–449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sasaki, H.; Sunagawa, Y.; Takahashi, K.; Imaizumi, A.; Fukuda, H.; Hashimoto, T.; Wada, H.; Katanasaka, Y.; Kakeya, H.; Fujita, M.; et al. Innovative preparation of curcumin for improved oral bioavailability. Biol. Pharm. Bull. 2011, 34, 660–665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Type of Nanoformulation | Admin. Route | Brain/Plasma | Effect | Measured Effect | Ref. |
---|---|---|---|---|---|
PLGA | IV (20 mg/kg) | Brain | Increment | Free Curcumin 500 µg/g (wet tissue) | [32] |
Nano Curcumin 1400 µg/g (wet tissue) | |||||
PVP | Oral (60 mg/kg) | Plasma | Increment | Free Curcumin 0.7 ng/mL | [37] |
Nano Curcumin 109 ng/mL | |||||
Copolymer | IV (25 mg/kg) | Brain | Increment | Free Curcumin not tested | [39] |
Nano Curcumin 0.322 µg/g | |||||
(LDL)-mimic Nanoparticles -Lactoferrin | IV (10 mg/kg) | Plasma | Increment | Free Curcumin not detected | [41] |
Nano Curcumin 13.03 ng/mL | |||||
Solid Lipid Nanoparticles | IV (50 mg/kg) | Brain | Increment | Increased association of nanoformulated Curcumin with amyloids plagues. No quantitative data | [42] |
Red blood cells camouflaged—Albumin NPs | IV (5 mg/kg) | Brain | Increment | Free Curcumin 0.05% of inj. Cur./g brain | [43] |
Nano Curcumin 0.25% of inj. Cur./g brain | |||||
Theracurcumin® | Oral (300 mg/kg) | Plasma | Increment | Free Curcumin 0 ng/mL | [44] |
Nano Curcumin 1600 ng/mL |
Treatments | Preclinical Trial in AD Model | Citation | |||||
---|---|---|---|---|---|---|---|
Behavioural Impairment: ↓ towards Normal Levels or ↑ Away from Normal Levels | Neuropathology: ↓ Towards Normal Levels or ↑ Away from Normal Levels | ||||||
Morris water maze | Brain oxidative stress marker 1 | Degenerating neurons | Kakkar et al., 2011 | ||||
Solid lipid nanoparticles containing curcumin | ↓↓ | ↓ | ↓ 2 | ||||
Curcumin | ↓ | - | - 2 | ||||
Morris water maze | Astrocytes, Microglia 3 | Hf neuronal loss | Gao, Wang et al., 2020 | ||||
Red blood cell-membrane-camouflaged human serum albumin nanoparticles loaded with curcumin and bearing T807 and triphenylphosphine | ↓↓ | ↓ | ↓ | ||||
RBC-membrane-camouflaged HSA NPs loaded with curcumin and bearing T807 | - | - | - | ||||
RBC-membrane-camouflaged HSA NPs loaded with curcumin and bearing triphenylphosphine | - | - | - | ||||
RBC-membrane-camouflaged HSA NPs loaded with curcumin | - | - | - | ||||
Curcumin | - | - | - | ||||
Morris water maze | Astrocytes, Microglia 3 | Hf neuronal loss | Gao, Chu et al., 2020 | ||||
Red blood cell membrane-coated PLGA particles carrying T807 molecules and loaded with curcumin | ↓ | ↓ | ↓↓ | ||||
RBC membrane-coated PLGA particles loaded with curcumin | - | - | ↓ | ||||
RBC membrane-coated PLGA particles carrying T807 molecules | - | - | - | ||||
Curcumin | - | - | - | ||||
Morris water maze | Inflammatory cytokine expression in brain | Giacomeli et al., 2019 | |||||
Lipid-core nanocapsules loaded with curcumin | ↓ | ↓ | |||||
Curcumin | ↓ | ↓ | |||||
Radial arm maze | Contextual fear conditioning | Plaque area | Cheng et al., 2013 | ||||
Polyethyleneglycol-polylactide di-block polymer micelles loaded with curcumin | - | - | - | ||||
Curcumin | - | - | ↓ | ||||
Morris water maze | Tau dimers | Hf synaptic protein abnormal distribution | Ma et al., 2013 | ||||
Solid lipid nanoparticle curcumin (Longvida) | ↓ | ↓ | ↓ | ||||
Two-trial Y maze | Novel object recognition | Astrocytes, Microglia 3 | Plaque area | Hf synaptic number 4 | Huang et al., 2017 | ||
Poly (lactide-co-glycolide) nanoparticles conjugated with cyclic CRTIGPSVC peptide and loaded with curcumin and Aβ generation inhibitor S1 | ↓↓ | ↓ | ↓↓ | ↓↓ | ↓ | ||
PLGA nanoparticles loaded with curcumin and Aβ generation inhibitor S1 | ↓ | ↓ | ↓↓ | ↓↓ | ↓ | ||
PLGA nanoparticles loaded with curcumin | ↓ | - | ↓ | - | - | ||
PLGA nanoparticles loaded with Aβ generation inhibitor S1 | ↓ | - | - | ↓ | - | ||
Morris water maze | Plaque burden | Fan et al., 2018 | |||||
Poly (lactide-co-glycolide) nanoparticles conjugated with B6 peptide and loaded with curcumin | ↓ | ↓ | |||||
PLGA nanoparticles loaded with curcumin | ↓ | ↓ | |||||
Curcumin | ↓ | ↓ |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gagliardi, S.; Morasso, C.; Stivaktakis, P.; Pandini, C.; Tinelli, V.; Tsatsakis, A.; Prosperi, D.; Hickey, M.; Corsi, F.; Cereda, C. Curcumin Formulations and Trials: What’s New in Neurological Diseases. Molecules 2020, 25, 5389. https://doi.org/10.3390/molecules25225389
Gagliardi S, Morasso C, Stivaktakis P, Pandini C, Tinelli V, Tsatsakis A, Prosperi D, Hickey M, Corsi F, Cereda C. Curcumin Formulations and Trials: What’s New in Neurological Diseases. Molecules. 2020; 25(22):5389. https://doi.org/10.3390/molecules25225389
Chicago/Turabian StyleGagliardi, Stella, Carlo Morasso, Polychronis Stivaktakis, Cecilia Pandini, Veronica Tinelli, Aristides Tsatsakis, Davide Prosperi, Miriam Hickey, Fabio Corsi, and Cristina Cereda. 2020. "Curcumin Formulations and Trials: What’s New in Neurological Diseases" Molecules 25, no. 22: 5389. https://doi.org/10.3390/molecules25225389
APA StyleGagliardi, S., Morasso, C., Stivaktakis, P., Pandini, C., Tinelli, V., Tsatsakis, A., Prosperi, D., Hickey, M., Corsi, F., & Cereda, C. (2020). Curcumin Formulations and Trials: What’s New in Neurological Diseases. Molecules, 25(22), 5389. https://doi.org/10.3390/molecules25225389